阿帕替尼二线治疗小细胞肺癌的疗效分析  

Analysis of efficacy of Apatinib second line in the treatment of small cell lung cancer

作　　者：郭秀梅[1] 林雪 王雷[1] 高丽华 王悦申 GUO Xiu-mei;LIN Xue;WANG Lei(Department of Oncology,The People＇s Hospital of Jilin City,Jilin 132001,China)

机构地区：[1]吉林市人民医院肿瘤内科,132001

出　　处：《中国现代药物应用》2018年第21期62-63,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨阿帕替尼二线治疗小细胞肺癌的临床疗效。方法 30例一线治疗后复发及转移的小细胞肺癌患者作为研究对象,给予患者阿帕替尼进行二线治疗,观察患者治疗效果及不良反应发生情况。结果 30例患者均可评价疗效,无一例完全缓解、6例(20%)部分缓解、16例(53%)疾病稳定、8例(27%)疾病进展,总缓解率为20%(6/30),疾病控制率73%(22/30)。本研究药物不良反应主要为高血压、手足综合征、蛋白尿,其中高血压11例(37%),均为2级以下,手足综合征8例(27%),蛋白尿6例(20%),用药过程中虽然伴随着不良反应,但通过中断药物或降低剂量,不良反应呈现出可控性和耐受性。结论阿帕替尼二线治疗小细胞肺癌具有一定的临床疗效,能够改善患者生活质量,且不良反应可控,能够作为二线治疗小细胞肺癌可选择的靶向药物。Objective To investigate the clinical efficacy of Apatinib second line in the treatment of small cell lung cancer. Methods A total of 30 small cell lung cancer patients with recurrence and metastasis after first line treatment were selected as research objects, they were given second line treatment with Apatinib. The therapeutic effect and occurrence of adverse reactions between the two groups were observed. Results None of 30 patients had complete remission, 6 cases （20%） were partial remission, 16 cases （53%） were stable disease, 8 cases （27%） were progressive disease, the overall remission rate was 20%（6/30） and the disease control rate was 73%（22/30）. The main adverse drug reactions in this study were hypertension, hand foot syndrome and proteinuria. Among them, 11 cases （37%） were hypertension and all below grade 2, 8 cases （27%） were hand foot syndrome, and 6 cases （20%） were proteinuria. Although adverse reactions are accompanied by drug use, the adverse reactions are controllable and tolerable by interrupting the drug or reducing the dose. Conclusion Apatinib second line treatment of small cell lung cancer has a certain clinical efficacy, can improve the quality of life of patients, and adverse reactions can be controlled, it can be used as a selective targeted drug for second line treatment of small cell lung cancer.

关 键 词：阿帕替尼 二线治疗 小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]